A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. (Q34322964)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

main subject

schizophrenia

0 references

cognitive dysfunction

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

George M Haig

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Earle Bain

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Weining Robieson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jeffrey Baker

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Robert A Lenz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

English

0 references

publication date

10 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

published in

Schizophrenia Bulletin

1 reference

1 August 2017

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

1433-1442

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers

7 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Histamine in neurotransmission and brain diseases.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

The histamine H3 receptor: from discovery to clinical trials with pitolisant

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

The histamine H3 receptor: an attractive target for the treatment of cognitive disorders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Cognition in schizophrenia: impairments, determinants, and functional importance

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

The positive and negative syndrome scale (PANSS) for schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

A rating scale for drug-induced akathisia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193706

Cognitive functions in prepsychotic patients.

6 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT240

Stability and course of neuropsychological deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT240

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT240

Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT240

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT240

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT240

Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT240

The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24516190

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Reliability and validity of a depression rating scale for schizophrenics

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24516190

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/SCHBUL/SBT240

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24516190%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference